Financial Results for the Fiscal Year Ending March 2026 – Consolidated Financial Statements

Financial Performance Overview

Net sales for the fiscal year ending March 2026 were 81.3 billion yen (up 8.1 billion yen YoY), with recovery in sales for healthcare products in Europe, North America, and China exceeding the previous year's figures. Conversely, sales for B&P and Creative Work segments remained low due to economic downturns in major regions such as Europe. Operating profit was 2.36 billion yen (down 1.34 billion yen YoY), impacted by approximately 400 million yen in inventory evaluation losses, wage increases, expenses related to new technology buildings, and expanded sales activities in India and the Middle East, resulting in a loss. Net income attributable to owners of the parent was 7.32 billion yen (up 3.17 billion yen YoY), aided by a gain of 7.99 billion yen from the sale of investment securities including policy-held shares and other investment-purpose shares.

Market Trends and Financial Position

By market, healthcare sales increased from 42.4% to 45.0%, with sales recovering in Europe and North America. B&P sales lagged due to stagnation in Europe’s economy. Creative Work demand was slow to recover in Europe. V&S sales decreased due to postponed orders for air traffic control applications, though ship-related sales remained strong. Amusement industry continued to face a challenging environment due to overall industry contraction. On the balance sheet, total assets increased to 177.48 billion yen (up 19.72 billion yen from the previous year), reflecting growth in capital investment and investment securities. Research and development expenses were 6.86 billion yen (up 102.2% YoY), and capital expenditure was 4.66 billion yen (up 4.4% YoY).